By applying transcription analysis to study the Shexiang Baoxin pill (SBP) in atherosclerosis treatment, key target genes (MAPK3, AKT1, and STAT3) associated with the prescription’s efficacy were identified. The gene discussed is MAPK3; the disease is atherosclerosis.